Introduction: We have developed a fiducial imaging-guidance marker for prostate with less imaging-artifacts than the currently commercially available markers. The aim of this study was to evaluate the imaging-artifact and potential usefulness and safety of the novel fiducial imaging-marker under the preclinical experiments.
Materials and Methods: We selected the specific metal materials and shape that can minimize artifacts, under having obtained a license for a metal with a gold-platinum (Au-Pt) alloy composition that maximized artifact-free MRI images. The both phantom test and dog-prostate test were conducted in order to evaluate the imaging-artifacts for three imaging modalities of MRI, CT, and ultrasound, and also the risk of migration of the markers from inserted site to other as well as their crushing.
Results: Newly developed Au-Pt material is less imaging-artifact for all of MRI, CT, and ultrasound imaging modalities in comparison to currently commercially available fiducial markers made by gold material only, and the Au-Pt markers had sufficient strength and durability, and is considered as potential clinically useful and safe marker.
Conclusion: The developed Au-Pt marker can be an indispensable device for accurate lesion-targeted organ-preserving therapy such as lesion-targeted focal therapy and active surveillance, than the conventional whole-gland surgical or radiation therapy.